VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac®, which is approved for use in Israel and 10 other countries and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus (CMV) expertise with the eVLP platform technology, VBI’s lead eVLP program candidates include a prophylactic CMV vaccine candidate and a glioblastoma (GBM) vaccine immunotherapeutic candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Phone: +1 617-830-3031
Total raised: $50M
Founded date: 2001
Investors 4
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | K2 HealthV... | k2healthve... |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.05.2020 | - | $50M | - |
Mentions in press and media 26
| Date | Title | Description |
| 31.12.2024 | Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study | Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for... |
| 14.05.2024 | Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies | DURHAM, N.C. and BEIJING, May 14, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across... |
| 22.03.2024 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results | Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring fu... |
| 27.12.2021 | Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B | DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 09.12.2021 | VBI Vaccines : Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada - Form 8-K | VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada CAMBRIDGE, Mass. (December 9, 2021) - VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pu... |
| 02.12.2021 | VBI Vaccines : to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021 - Form 8-K | VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021 ● Updated 12-month and 18-month overall survival data demonstrate continued improvements compared ... |
| 01.12.2021 | VBI Vaccines : Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults - Form 8-K | VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults - PreHevbrio™ is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - Shareholder conference call to be held today, December ... |
| 08.11.2021 | VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Hepatitis B (HBV) : ● Prophylactic : FDA and EMA regulatory review of VBI's 3-antigen prophylactic HBV vaccine candidate ongoing - U.S. PDUFA target... |
| 01.11.2021 | VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic - Form 8-K | VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021 CAMBRIDGE, Mass. (November 1, 2021) - VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by i... |
| 14.10.2021 | VBI Vaccines : Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association N... | VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced that results from the pivotal Phase 3 study, CONSTANT, of VBI's prophylactic ... |
Show more